MBX Biosciences is a preclinical-stage biotech company that creates therapies to treat rare endocrine diseases.
MBX Biosciences has raised $63.5M in total funding. The most recent round was Series C. The last funding was announced in August 2024.
MBX Biosciences's investors include Norwest Venture Partners, New Enterprise Associates, Wellington Management, OrbiMed, RA Capital Management.
MBX Biosciences is headquartered in Carmel, United States.
MBX Biosciences is a preclinical-stage biotech company that creates therapies to treat rare endocrine diseases.
MBX Biosciences is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MBX Biosciences — Funding & Investors." VCBacked, August 5, 2024, https://www.vcbacked.co/company/mbx-biosciences. Accessed July 19, 2026.
VCBacked. (2024). MBX Biosciences — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/mbx-biosciences
{{cite web |title=MBX Biosciences — Funding & Investors |url=https://www.vcbacked.co/company/mbx-biosciences |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated